|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression |
ISO |
2-amino-4-hydroxy-6-formylpteridine results in decreased expression of BID protein |
CTD |
PMID:16019850 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
2-amino-4-hydroxy-6-formylpteridine results in increased activity of CASP3 protein |
CTD |
PMID:16019850 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
2-amino-4-hydroxy-6-formylpteridine results in increased activity of CASP8 protein |
CTD |
PMID:16019850 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
2-amino-4-hydroxy-6-formylpteridine affects the localization of CYCS protein |
CTD |
PMID:16019850 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Prkcd |
protein kinase C, delta |
affects localization |
ISO |
2-amino-4-hydroxy-6-formylpteridine affects the localization of PRKCD protein |
CTD |
PMID:16019850 |
|
NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
Allopurinol promotes the reaction [Acetylcysteine inhibits the reaction [Streptozocin results in decreased expression of ADIPOQ mRNA]]; Allopurinol promotes the reaction [Acetylcysteine inhibits the reaction [Streptozocin results in decreased expression of ADIPOQ protein]] |
CTD |
PMID:21912612 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Adipor2 |
adiponectin receptor 2 |
multiple interactions |
EXP |
Allopurinol promotes the reaction [Acetylcysteine inhibits the reaction [Streptozocin results in decreased expression of ADIPOR2 protein]] |
CTD |
PMID:21912612 |
|
NCBI chr 4:151,412,135...151,480,108
Ensembl chr 4:151,414,684...151,428,894
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [AGT protein results in increased abundance of Reactive Oxygen Species]; Allopurinol inhibits the reaction [AGT protein results in increased expression of PTGS2 protein] |
CTD |
PMID:17244722 PMID:19145780 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
EXP |
Allopurinol results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:28138970 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
EXP |
Allopurinol results in increased expression of ALPL mRNA |
CTD |
PMID:26968635 |
|
NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
EXP |
Allopurinol results in increased expression of BGLAP mRNA |
CTD |
PMID:26968635 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [Glucose results in increased expression of CASP1 protein] Allopurinol inhibits the reaction [Fructose results in increased expression of CASP1 protein modified form]; Allopurinol inhibits the reaction [Fructose results in increased expression of CASP1 protein]; Allopurinol inhibits the reaction [Glucose results in increased expression of CASP1 protein]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of CASP1 mRNA]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of CASP1 protein] |
CTD |
PMID:22426011 PMID:23647015 PMID:24491314 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Indomethacin results in decreased activity of CAT protein] |
CTD |
PMID:12566098 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased secretion of CCL17 protein]; Allopurinol inhibits the reaction [TNF protein results in increased expression of CCL17 mRNA] |
CTD |
PMID:28949055 |
|
NCBI chr19:10,619,220...10,620,671
Ensembl chr19:10,619,220...10,620,671
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
Allopurinol inhibits the reaction [[Fructose co-treated with Uric Acid] results in increased secretion of CCL2 protein]; Allopurinol inhibits the reaction [Fructose results in increased secretion of CCL2 protein]; pyrazolanthrone inhibits the reaction [Allopurinol results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Allopurinol results in increased expression of CCL2 mRNA]; U 0126 inhibits the reaction [Allopurinol results in increased expression of CCL2 mRNA] Allopurinol inhibits the reaction [sodium arsenite results in increased expression of CCL2 mRNA] |
CTD |
PMID:15689417 PMID:19158351 PMID:26641773 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased secretion of CCL22 protein]; Allopurinol inhibits the reaction [TNF protein results in increased expression of CCL22 mRNA] |
CTD |
PMID:28949055 |
|
NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
EXP |
Allopurinol results in increased expression of CD36 mRNA |
CTD |
PMID:28138970 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [nickel chloride results in decreased expression of CDH1 protein] |
CTD |
PMID:22648416 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Ckm |
creatine kinase, M-type |
decreases secretion |
EXP |
Allopurinol results in decreased secretion of CKM protein |
CTD |
PMID:21912612 |
|
NCBI chr 1:80,321,507...80,331,841
Ensembl chr 1:80,321,585...80,331,841
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [vanadium pentoxide results in increased expression of CXCL10 mRNA] |
CTD |
PMID:18322232 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
decreases expression |
EXP |
Allopurinol results in decreased expression of ENPP1 mRNA |
CTD |
PMID:26968635 |
|
NCBI chr 1:21,748,201...21,813,205
Ensembl chr 1:21,748,261...21,813,371
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [Glucose results in increased expression of FASN protein] Allopurinol inhibits the reaction [Glucose results in increased expression of FASN protein]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of FASN mRNA]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of FASN protein] |
CTD |
PMID:23647015 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [nickel chloride results in increased expression of FN1 protein] |
CTD |
PMID:22648416 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Allopurinol results in increased expression of FOS mRNA |
CTD |
PMID:12730611 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Fructose results in decreased expression of GLUL protein] |
CTD |
PMID:24491314 |
|
NCBI chr13:71,331,052...71,340,207
Ensembl chr13:71,331,052...71,340,229
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [ammonium acetate results in decreased expression of GRIN2A protein] |
CTD |
PMID:20084674 |
|
NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Indomethacin results in decreased activity of GSR protein] |
CTD |
PMID:12566098 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Allopurinol inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]; Allopurinol inhibits the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA] Allopurinol results in increased expression of HMOX1 mRNA |
CTD |
PMID:20888885 PMID:22659318 PMID:25091725 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [vanadium pentoxide results in increased expression of IFNB1 mRNA] |
CTD |
PMID:18322232 |
|
NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased phosphorylation of RELA protein]; Allopurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased secretion of CCL17 protein]; Allopurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased secretion of CCL22 protein] |
CTD |
PMID:28949055 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Fructose results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:24491314 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Fructose results in increased expression of IL18 protein]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of IL18 protein] |
CTD |
PMID:22426011 PMID:23647015 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO EXP |
Allopurinol results in decreased expression of IL1B mRNA Allopurinol inhibits the reaction [Fructose results in increased expression of IL1B protein]; Allopurinol inhibits the reaction [Glucose results in increased expression of IL1B protein]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of IL1B protein] |
CTD |
PMID:7695923 PMID:22426011 PMID:23647015 PMID:24491314 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [Lipopolysaccharides promotes the reaction [NFAT5 protein binds to IL6 promoter]] Allopurinol inhibits the reaction [Fructose results in increased expression of IL6 protein]; Allopurinol inhibits the reaction [sodium arsenite results in increased expression of IL6 mRNA]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of IL6 protein] |
CTD |
PMID:15689417 PMID:21912612 PMID:22426011 PMID:23867654 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Insr |
insulin receptor |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Fructose results in decreased phosphorylation of INSR protein] |
CTD |
PMID:22426011 PMID:24491314 |
|
NCBI chr12:1,682,527...1,816,414
Ensembl chr12:1,680,957...1,816,414
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Fructose results in decreased phosphorylation of IRS1 protein] |
CTD |
PMID:22426011 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Fructose results in increased expression of LEP protein] |
CTD |
PMID:22426011 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Fructose results in increased expression of and results in increased phosphorylation of LEPR protein] |
CTD |
PMID:22426011 |
|
NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
|
|
G |
Lgals9 |
galectin 9 |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Fructose results in decreased expression of LGALS9 mRNA]; Allopurinol inhibits the reaction [Fructose results in decreased expression of LGALS9 protein] |
CTD |
PMID:19605544 |
|
NCBI chr10:64,737,022...64,760,195
Ensembl chr10:64,737,022...64,760,201
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Allopurinol results in increased phosphorylation of MAPK1 protein U 0126 inhibits the reaction [Allopurinol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:26641773 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:15650392 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Allopurinol results in increased phosphorylation of MAPK3 protein U 0126 inhibits the reaction [Allopurinol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:26641773 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [Acrolein results in increased expression of MMP9 protein] |
CTD |
PMID:19371603 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Indomethacin results in increased activity of MPO protein] |
CTD |
PMID:12566098 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [Lipopolysaccharides promotes the reaction [NFAT5 protein binds to IL6 promoter]]; Allopurinol inhibits the reaction [Lipopolysaccharides results in increased expression of NFAT5 mRNA] Allopurinol inhibits the reaction [Oxonic Acid affects the localization of NFAT5 protein] |
CTD |
PMID:23867654 PMID:30651350 |
|
NCBI chr19:38,446,059...38,533,735
Ensembl chr19:38,446,059...38,533,735
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Fructose results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:24491314 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [Glucose results in increased expression of NLRP3 protein] Allopurinol inhibits the reaction [Fructose results in increased expression of NLRP3 protein]; Allopurinol inhibits the reaction [Glucose results in increased expression of NLRP3 protein]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of NLRP3 mRNA]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of NLRP3 protein] |
CTD |
PMID:22426011 PMID:23647015 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Streptozocin results in decreased phosphorylation of NOS3 protein]; Allopurinol promotes the reaction [Acetylcysteine inhibits the reaction [Streptozocin results in decreased phosphorylation of NOS3 protein]] |
CTD |
PMID:21912612 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
EXP ISO |
Allopurinol inhibits the reaction [Glucose results in increased expression of NR1H3 protein]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of NR1H3 mRNA]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of NR1H3 protein] |
CTD |
PMID:23647015 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [Glucose results in decreased expression of PPARA protein] Allopurinol inhibits the reaction [Fructose results in decreased expression of PPARA protein]; Allopurinol inhibits the reaction [Glucose results in decreased expression of PPARA protein]; Allopurinol inhibits the reaction [Streptozocin results in decreased expression of PPARA mRNA]; Allopurinol inhibits the reaction [Streptozocin results in decreased expression of PPARA protein] |
CTD |
PMID:22426011 PMID:23647015 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [AGT protein results in increased expression of PTGS2 protein] |
CTD |
PMID:17244722 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP ISO |
Allopurinol inhibits the reaction [Fructose results in increased expression of PYCARD protein]; Allopurinol inhibits the reaction [Glucose results in increased expression of PYCARD protein]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of PYCARD mRNA]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of PYCARD protein] |
CTD |
PMID:22426011 PMID:23647015 |
|
NCBI chr 1:199,438,029...199,439,062
Ensembl chr 1:199,437,832...199,439,210
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
Allopurinol inhibits the reaction [Fructose results in increased phosphorylation of RELA protein] Allopurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:24491314 PMID:28949055 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 mRNA]; Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein] Allopurinol inhibits the reaction [Fructose results in decreased expression of SLC22A1 mRNA]; Allopurinol inhibits the reaction [Fructose results in decreased expression of SLC22A1 protein] |
CTD |
PMID:19605544 PMID:21909718 PMID:22865646 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a12 |
solute carrier family 22 member 12 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein] Allopurinol inhibits the reaction [Fructose results in increased expression of SLC22A12 mRNA]; Allopurinol inhibits the reaction [Fructose results in increased expression of SLC22A12 protein] |
CTD |
PMID:19605544 PMID:21909718 PMID:22865646 |
|
NCBI chr 1:221,910,787...221,919,277
Ensembl chr 1:221,910,767...221,919,301
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 mRNA]; Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A2 protein] Allopurinol inhibits the reaction [Fructose results in decreased expression of SLC22A2 mRNA]; Allopurinol inhibits the reaction [Fructose results in decreased expression of SLC22A2 protein] |
CTD |
PMID:19605544 PMID:21909718 PMID:22865646 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 mRNA]; Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein] |
CTD |
PMID:21909718 PMID:22865646 |
|
NCBI chr10:39,334,972...39,373,508
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 mRNA]; Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein] Allopurinol inhibits the reaction [Fructose results in decreased expression of SLC22A5 protein] |
CTD |
PMID:21909718 PMID:22426011 PMID:22865646 |
|
NCBI chr10:39,201,101...39,228,090
Ensembl chr10:39,201,107...39,323,853
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein] Allopurinol inhibits the reaction [Fructose results in decreased expression of SLC22A6 mRNA]; Allopurinol inhibits the reaction [Fructose results in decreased expression of SLC22A6 protein] |
CTD |
PMID:19605544 PMID:21909718 PMID:22865646 |
|
NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
increases transport increases uptake |
ISO |
SLC22A7 protein results in increased transport of Allopurinol SLC22A7 protein results in increased uptake of Allopurinol |
CTD |
PMID:12065749 PMID:15901346 |
|
NCBI chr 9:16,925,321...16,931,119
Ensembl chr 9:16,924,520...16,931,766
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases transport |
ISO |
SLC22A8 protein results in increased transport of Allopurinol |
CTD |
PMID:15100168 |
|
NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
|
|
G |
Slc2a9 |
solute carrier family 2 member 9 |
multiple interactions |
EXP |
Allopurinol inhibits the reaction [Fructose results in increased expression of SLC2A9 mRNA SNP]; Allopurinol inhibits the reaction [Fructose results in increased expression of SLC2A9 protein SNP] |
CTD |
PMID:19605544 |
|
NCBI chr14:77,067,537...77,192,702
Ensembl chr14:77,067,503...77,192,702
|
|
G |
Slc5a3 |
solute carrier family 5 member 3 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [Lipopolysaccharides inhibits the reaction [Sodium Chloride results in increased expression of SLC5A3 mRNA]] |
CTD |
PMID:23867654 |
|
NCBI chr11:32,229,366...32,231,812
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [Glucose results in increased expression of SREBF1 protein] Allopurinol inhibits the reaction [Glucose results in increased expression of SREBF1 protein]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of SREBF1 mRNA]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of SREBF1 protein] |
CTD |
PMID:23647015 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [Glucose results in increased expression of SREBF2 protein] Allopurinol inhibits the reaction [Glucose results in increased expression of SREBF2 protein]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of SREBF2 mRNA]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of SREBF2 protein] |
CTD |
PMID:23647015 |
|
NCBI chr 7:123,381,082...123,438,605
Ensembl chr 7:123,381,077...123,438,603
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [vanadium pentoxide results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:18322232 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Allopurinol promotes the reaction [Acetylcysteine inhibits the reaction [Streptozocin results in decreased phosphorylation of STAT3 protein]] |
CTD |
PMID:21912612 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
affects activity |
EXP |
Allopurinol affects the activity of TDO2 protein |
CTD |
PMID:7306070 |
|
NCBI chr 2:180,897,059...180,914,919
Ensembl chr 2:180,897,011...180,914,940
|
|
G |
Tnf |
tumor necrosis factor |
increases chemical synthesis increases expression multiple interactions |
ISO EXP |
TNF protein results in increased chemical synthesis of Allopurinol Allopurinol results in increased expression of TNF mRNA Allopurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased phosphorylation of RELA protein]; Allopurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased secretion of CCL17 protein]; Allopurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased secretion of CCL22 protein]; Allopurinol inhibits the reaction [TNF protein results in increased expression of CCL17 mRNA]; Allopurinol inhibits the reaction [TNF protein results in increased expression of CCL22 mRNA]; U 0126 inhibits the reaction [Allopurinol results in increased expression of TNF mRNA] Allopurinol inhibits the reaction [Fructose results in increased expression of TNF protein] |
CTD |
PMID:7695923 PMID:22426011 PMID:26641773 PMID:28949055 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions |
ISO EXP |
Allopurinol inhibits the reaction [Glucose results in increased expression of TXNIP protein] Allopurinol inhibits the reaction [Fructose results in increased expression of TXNIP protein]; Allopurinol inhibits the reaction [Glucose results in increased expression of TXNIP protein]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of TXNIP mRNA]; Allopurinol inhibits the reaction [Streptozocin results in increased expression of TXNIP protein] |
CTD |
PMID:23647015 PMID:24491314 |
|
NCBI chr 2:198,683,168...198,686,971
Ensembl chr 2:198,683,159...198,686,974
|
|
G |
Umod |
uromodulin |
multiple interactions |
ISO |
Allopurinol inhibits the reaction [potassium oxonate affects the expression of UMOD protein]; Allopurinol inhibits the reaction [potassium oxonate results in increased expression of UMOD mRNA] |
CTD |
PMID:21909718 |
|
NCBI chr 1:189,186,027...189,199,939
Ensembl chr 1:189,186,026...189,199,376
|
|
G |
Xdh |
xanthine dehydrogenase |
decreases activity multiple interactions affects activity |
ISO EXP |
Allopurinol results in decreased activity of XDH protein Allopurinol inhibits the reaction [[Streptozocin affects the activity of XDH protein] which results in increased chemical synthesis of Hydrogen Peroxide]; Allopurinol inhibits the reaction [Indomethacin results in increased activity of XDH protein]; Allopurinol inhibits the reaction [Streptozocin affects the activity of XDH protein]; Allopurinol inhibits the reaction [XDH protein results in increased oxidation of Quinoxalines] Allopurinol affects the activity of XDH protein Allopurinol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of XDH protein] |
CTD |
PMID:1447108 PMID:3677084 PMID:8891675 PMID:12115777 PMID:12566098 PMID:12694877 PMID:12826072 PMID:14982945 PMID:17439425 PMID:19933411 PMID:20142047 PMID:21939274 PMID:23647015 PMID:26968635 |
|
NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
|
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
EXP |
Oxypurinol results in increased expression of ALPL mRNA |
CTD |
PMID:26968635 |
|
NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
EXP |
Oxypurinol results in increased expression of BGLAP mRNA |
CTD |
PMID:26968635 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
multiple interactions |
ISO |
Oxypurinol inhibits the reaction [TNF protein results in increased expression of CCL17 mRNA] |
CTD |
PMID:28949055 |
|
NCBI chr19:10,619,220...10,620,671
Ensembl chr19:10,619,220...10,620,671
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Oxypurinol results in increased expression of CCL2 mRNA |
CTD |
PMID:26641773 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
ISO |
Oxypurinol inhibits the reaction [TNF protein results in increased expression of CCL22 mRNA] |
CTD |
PMID:28949055 |
|
NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
Oxypurinol results in increased expression of CXCL10 mRNA |
CTD |
PMID:25091725 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Dek |
DEK proto-oncogene |
increases secretion |
ISO |
DEK protein results in increased secretion of Oxypurinol |
CTD |
PMID:28558019 |
|
NCBI chr17:17,965,872...17,987,836
Ensembl chr17:17,965,881...17,987,834
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
decreases expression |
EXP |
Oxypurinol results in decreased expression of ENPP1 mRNA |
CTD |
PMID:26968635 |
|
NCBI chr 1:21,748,201...21,813,205
Ensembl chr 1:21,748,261...21,813,371
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Oxypurinol results in increased expression of HMOX1 mRNA |
CTD |
PMID:25091725 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Oxypurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:28949055 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Oxypurinol inhibits the reaction [Acrolein results in increased expression of MMP9 protein] |
CTD |
PMID:19371603 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Oxypurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:28949055 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Slc22a12 |
solute carrier family 22 member 12 |
multiple interactions increases uptake |
ISO |
Benzbromarone inhibits the reaction [SLC22A12 protein results in increased uptake of Oxypurinol]; Uric Acid inhibits the reaction [SLC22A12 protein results in increased uptake of Oxypurinol] |
CTD |
PMID:16135657 |
|
NCBI chr 1:221,910,787...221,919,277
Ensembl chr 1:221,910,767...221,919,301
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
Oxypurinol results in increased expression of TNF mRNA Oxypurinol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased phosphorylation of RELA protein]; Oxypurinol inhibits the reaction [TNF protein results in increased expression of CCL17 mRNA]; Oxypurinol inhibits the reaction [TNF protein results in increased expression of CCL22 mRNA] |
CTD |
PMID:26641773 PMID:28949055 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Xdh |
xanthine dehydrogenase |
decreases activity |
EXP |
Oxypurinol results in decreased activity of XDH protein |
CTD |
PMID:26968635 |
|
NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
aspalathin inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; aspalathin inhibits the reaction [Glucose results in increased expression of CCL2 protein] |
CTD |
PMID:25338943 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
ISO |
aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein]; aspalathin inhibits the reaction [[TNF protein co-treated with F7 protein] results in increased expression of F10 protein] |
CTD |
PMID:25325928 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
ISO |
aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
F5 |
coagulation factor V |
multiple interactions |
ISO |
aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr13:82,479,997...82,535,540
Ensembl chr13:82,479,998...82,535,534
|
|
G |
F7 |
coagulation factor VII |
multiple interactions |
ISO |
aspalathin inhibits the reaction [[TNF protein co-treated with F7 protein] results in increased expression of F10 protein] |
CTD |
PMID:25325928 |
|
NCBI chr16:81,824,610...81,834,923
Ensembl chr16:81,824,111...81,834,945
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
aspalathin inhibits the reaction [Glucose results in increased expression of ICAM1 protein]; aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ICAM1 mRNA]; aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ICAM1 protein] |
CTD |
PMID:25338943 PMID:25655391 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein] |
CTD |
PMID:25655391 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:25655391 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:25655391 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] |
CTD |
PMID:25655391 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
aspalathin inhibits the reaction [Glucose affects the localization of RELA protein]; aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of RELA protein] |
CTD |
PMID:25338943 PMID:25655391 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
aspalathin inhibits the reaction [Glucose results in increased expression of SELE protein]; aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELE mRNA]; aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELE protein] |
CTD |
PMID:25338943 PMID:25655391 |
|
NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
aspalathin inhibits the reaction [TNF protein results in increased secretion of SERPINE1 protein] |
CTD |
PMID:25325928 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TLR4 protein] |
CTD |
PMID:25655391 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
aspalathin inhibits the reaction [[TNF protein co-treated with F7 protein] results in increased expression of F10 protein]; aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]; aspalathin inhibits the reaction [TNF protein results in increased secretion of SERPINE1 protein] |
CTD |
PMID:25325928 PMID:25655391 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
aspalathin inhibits the reaction [Glucose results in increased expression of VCAM1 protein]; aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of VCAM1 mRNA]; aspalathin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of VCAM1 protein] |
CTD |
PMID:25338943 PMID:25655391 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Paraquat results in decreased secretion of AGER protein modified form]; Febuxostat inhibits the reaction [Paraquat results in increased expression of AGER mRNA] |
CTD |
PMID:30726711 |
|
NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Doxorubicin results in increased expression of BAX protein] |
CTD |
PMID:26036690 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] |
CTD |
PMID:26036690 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein] |
CTD |
PMID:26036690 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Febuxostat results in increased expression of CCL2 mRNA |
CTD |
PMID:26641773 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Paraquat results in increased expression of CTNNB1 protein] |
CTD |
PMID:30726711 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
multiple interactions |
ISO |
Febuxostat inhibits the reaction [[myelin oligodendrocyte glycoprotein (35-55) co-treated with Freund's Adjuvant] results in decreased expression of GOT2 mRNA]; Febuxostat inhibits the reaction [[myelin oligodendrocyte glycoprotein (35-55) co-treated with Freund's Adjuvant] results in decreased expression of GOT2 protein] |
CTD |
PMID:29107957 |
|
NCBI chr19:9,587,637...9,613,323
Ensembl chr19:9,587,653...9,613,340
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Paraquat results in increased expression of HMGB1 mRNA] |
CTD |
PMID:30726711 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Doxorubicin results in increased expression of IKBKB protein] |
CTD |
PMID:26036690 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Paraquat results in increased expression of MMP9 protein] |
CTD |
PMID:30726711 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Doxorubicin results in increased expression of NPPB protein] |
CTD |
PMID:26036690 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Paraquat results in increased expression of PTGS2 mRNA] |
CTD |
PMID:30726711 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Doxorubicin results in increased expression of RELA protein] |
CTD |
PMID:26036690 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein] |
CTD |
PMID:26036690 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP ISO |
Febuxostat inhibits the reaction [Doxorubicin results in increased expression of TNF protein] Febuxostat results in increased expression of TNF mRNA |
CTD |
PMID:26036690 PMID:26641773 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Febuxostat inhibits the reaction [Paraquat results in increased expression of VEGFA protein] |
CTD |
PMID:30726711 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
pedalitin results in decreased activity of CYP1A2 protein |
CTD |
PMID:29753067 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
ISO |
pedalitin results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
ISO |
pedalitin results in decreased activity of CYP3A4 protein |
CTD |
PMID:29753067 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
purpurogallin inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine] |
CTD |
PMID:7710944 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|